eyestock logo

eyestock

TR

Tourmaline Bio IncNASDAQ TRML

Последний отчетный период 30 июня, 2024

Обновлено 12 нояб., 2024

Последняя цена

Капитализация млрд. $

0.442

Micro

Биржа

XNAS - Nasdaq

Анализ акций TRML

TR

Нет оценки

Количественный анализ Eyestock не покрывает акции Tourmaline Bio Inc.

Капитализация млрд. $

0.442

Дивидендная доходность

124.10 %

Оборот

25.65 млрд

Сайт компании

https://www.tourmalinebio.com/

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. The company is headquartered in New York City, New York and currently employs 44 full-time employees. The company went IPO on 2021-05-07. The firm is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Company’s initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. The company is also developing TOUR006 in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional diseases under consideration. The company is focused on two strategic paths for TOUR006, the first of which it refers to as FcRn+. Its second strategic path is cardiovascular inflammation.

Смотреть Секцию: Рейтинг